Longeveron is a clinical-stage biotechnology company at the forefront of developing cellular therapies for aging-related and life-threatening conditions. Through patient-focused regenerative medicine, Longeveron is dedicated to improving healthspan, which refers to the number of years a person can expect to live in good health, free from chronic disease and the disabilities of aging. Their research and therapies are designed to repair and regenerate damaged tissue within our own bodies.

Longeveron's primary focus is on aging-related chronic diseases and conditions, recognizing that as we age, our natural repair mechanisms become less effective. The company is a global leader in stem cell therapies, conducting phase 1 and 2 clinical trials for conditions such as Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's Disease, and Aging Frailty. HLHS is a congenital birth defect that affects the heart, while Alzheimer's Disease is a neurodegenerative disorder that leads to memory loss and death.

Aging Frailty refers to the increased vulnerability to adverse health outcomes as individuals grow older. With a team of experts and a commitment to advancing regenerative medicine, Longeveron is dedicated to improving the quality of life for patients with life-threatening conditions and addressing the challenges associated with aging